Abbas Kazimi Email & Phone Number

Abbas Kazimi is a Chief Executive Officer at Nimbus Therapeutics, Inc. based in Boston, Massachusetts, United States, North America. Abbas Kazimi is the Chief Executive Officer of Nimbus Therapeutics. Previously, he served as Chief Business Officer, leading the company’s strategic and corporate development efforts while overseeing business operations. Since joining Nimbus in 2014, he has helped raise over $630 million in equity financing and led corporate and business development transactions totaling over $8 billion. Notably, Mr. Kazimi spearheaded the $6 billion sale of Nimbus’s immunology, TYK2, program to Takeda ($4 billion in upfront cash), the $1.2 billion sale of its NASH program to Gilead ($400 million in upfront cash, $200 million in milestones received), and multiple licensing deals exceeding $1.5 billion in total value with partners such as Genentech, Celgene/BMS, and Eli Lilly. During his leadership, Nimbus has advanced four programs into the clinic, returned over $4 billion to investors, and continues to expand its computational drug discovery and clinical development capabilities. In 2025, Mr. Kazimi joined the board of Unnatural Products (UNP), a biotech company pioneering orally delivered macrocyclic peptides to tackle previously undruggable targets. He also serves on the Editorial Advisory Board for In Vivo magazine, a leading publication offering strategic insights and in-depth analysis of the pharmaceutical, biotechnology, medtech, and consumer health industries. His family is also a major supporter of various philanthropic initiatives and has recently been working with the teams at MD Anderson Cancer Center to drive data sciences into patient impact. At the core of Mr. Kazimi’s leadership is a deep sense of purpose—one that seeks to change the trajectory of a medical diagnosis where options are limited. The ability to give patients, prescribers, and families a new outlook on life is a powerful responsibility—and one he knows the Nimbus team is capable of delivering together.